In patients with early-stage tumors, the hormone receptor+/HER2– subtype exhibited the best OS, whereas patients with triple-negative and hormone receptor–/HER2+ BC had the poorest survival, with a HR of 1.69 (95% CI, 1.49 to 1.95; P < .0001) and 1.76 (95% CI, 1.42 to 2.17; P < .0001), respectively. Here, ERBB2 is linked to breast cancer.